Michael Narachi

CIK 1380022 · CEO & President · last filed 2026-05-18

Michael Narachi is a CEO & President who has filed 46 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for RARE, was dated May 18, 2026. Across all open-market trades the lifetime net is −$2.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $601.8K across reported positions. 14 SEC filings were submitted jointly with Ultragenyx Pharmaceutical Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$601.8K

Companies

Total Filings

Lifetime Open-Market Net

-$2.71M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address

C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO, CA 94949

Related Filers

Ultragenyx Pharmaceutical Inc. — 14 joint filings, latest 2026-05-18

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
RARE	Director	40,441	$14.88	$601.8K	$0	13	2026-05-18
Orexigen Therapeutics, Inc. (OREX) Delisted	CEO & President	8,356	—	—	-$3.24M	22	2017-10-17
Eiger BioPharmaceuticals, Inc. (CLDN) Delisted	Director	4,167	—	—	$500.0K	2	2015-06-05
AMAG PHARMACEUTICALS, INC. (AMAG) Delisted	Director	23,900	—	—	$27.1K	9	2013-05-24

Recent Filings

46 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-05-18	RARE	Grant (A)	+7,751	$0	EDGAR
2025-05-19	RARE	Grant (A)	+5,740	$0	EDGAR
2024-06-20	RARE	Grant (A)	+5,345	$0	EDGAR
2023-06-09	RARE	Grant (A)	+3,860	$0	EDGAR
2022-06-28	RARE	Grant (A)	+3,300	$0	EDGAR
2021-06-28	RARE	Grant (A)	+2,145	$0	EDGAR
2020-06-30	RARE	Grant (A)	+2,550	$0	EDGAR
2019-06-13	RARE	Grant (A)	+3,000	$0	EDGAR
2018-06-20	RARE	Grant (A)	+3,000	$0	EDGAR
2017-10-17	Orexigen Therapeutics, Inc. (OREX) Delisted	Grant (A)	—	$0	EDGAR

Showing 1–10 of 46

Page 1 of 5 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.